Arcturus Therapeutics

Focus: Arcturus Therapeutics is a San Diego-based biotech specializing in lipid nanoparticle (LNP) mRNA drug delivery systems for cardiovascular and gene therapy applications. The company operates as a clinical-stage developer with a diversified pipeline spanning infectious disease, genetic disorders, and rare metabolic conditions.

Cardiovascular Gene Therapy

Profile data last refreshed 18h ago · AI intelligence enriched 2w ago

Open Jobs

2+1 this month

Stable — net +1 jobs in 30d

2 added, 1 removed. Backfill posture.

Should You Work at Arcturus Therapeutics?

AI assessment

Best suited for R&D scientists seeking deep platform expertise in mRNA-LNP technology; poor fit for those seeking near-term role mobility or financial stability signals.

Why Work Here

Deep expertise in LNP-mRNA platform technology, a hot modality with regulatory validation from COVID-19 programs (ARCT-021 Phase 2, ARCT-2303 Phase 3).

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

ARCT-2138

Influenza

Phase 1

Clinical Trials (1)

NCT06125691Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults

Phase 1

Help build intelligence for Arcturus Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Diversified pipeline of 9 programs across 16 active trials reduces single-program risk and creates multiple inflection points for career advancement.

Rare metabolic and genetic disorder focus (cystic fibrosis, OTC deficiency) offers meaningful impact in underserved therapeutic areas.

Watch Out For

Only 1 active job opening signals minimal near-term hiring; limited lateral mobility or team expansion opportunities for new hires.
No commercialized products and phase distribution skewed toward early-stage (7 phase 1, 9 phase 2) creates long runway to revenue and cash burn risk.

Generated by Claude from Arcturus Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

ARCT-2304

Influenza

Phase 1

Clinical Trials (1)

NCT06602531Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults

Phase 1

ARCT-165

COVID-19

Phase 1/2

ARCT-021

COVID-19

Phase 2

Clinical Trials (5)

NCT04668339A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults

Phase 2

NCT07390968Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients

Phase 2

NCT04728347Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021

Phase 2

+2 more

ARCT-032

Cystic Fibrosis

Phase 2

Clinical Trials (2)

NCT06747858Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis

Phase 2

NCT05712538Safety, Tolerability, and Pharmacokinetics of ARCT-032 in Healthy Adult Subjects and Adults With Cystic Fibrosis.

Phase 1

ARCT-810

Ornithine Transcarbamylase Deficiency

Phase 2

Clinical Trials (4)

NCT06488313A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD

Phase 2

NCT05526066Study for Adolescents and Adults With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerability of ARCT-810

Phase 2

NCT04416126Safety, Tolerability and Pharmacokinetics of ARCT-810 in Healthy Adult Subjects

Phase 1

+1 more

ARCT-154

COVID-19

Phase 2/3

Clinical Trials (1)

NCT05012943The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01)

Phase 2/3

ARCT-2303

COVID-19

Phase 3

Clinical Trials (1)

NCT06279871Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults

Phase 3

Lymphatic Enhancement Technology

Fibromyalgia

Phase N/A

Clinical Trials (1)

NCT07201818LET for Fibromyalgia

N/A

Interview Prep Quick Facts

Portfolio: 16 clinical trials

Top TAs: Infectious Diseases, Rare Diseases, Oncology

Open Roles: 2 active jobs

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Infectious Diseases

6 pipeline

Rare Diseases

2 pipeline

Oncology

1 pipeline

Marketed

Pipeline

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Arcturus Therapeutics

Should You Work at Arcturus Therapeutics?

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Open Jobs (2)

Research Associate II/ Senior Research Associate I

Director, Head of Drug Discovery

Hiring Trend